Press Releases March 29, 2026 08:00 PM

BOSS Zhipin Surpasses RMB540 Million in Share Repurchases in 2026

KANZHUN LIMITED (BOSS Zhipin) accelerates share repurchases in 2026, exceeding RMB540 million

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
BZ

KANZHUN LIMITED, known as BOSS Zhipin, announced it has repurchased over RMB540 million worth of shares so far in 2026, including a recent purchase of RMB34.5 million on March 27. This substantial share repurchase program highlights the company's commitment to enhancing shareholder value.

BOSS Zhipin Surpasses RMB540 Million in Share Repurchases in 2026
BZ
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • BOSS Zhipin has repurchased RMB540 million worth of shares year-to-date in 2026.
  • The company repurchased 759,056 ordinary shares on March 27 for RMB34.5 million.
  • The share buyback demonstrates management’s confidence in the company's long-term prospects and commitment to shareholder returns.

BEIJING, March 30, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HK: 2076) today announced the continued execution of its share repurchase program, utilizing around RMB34.5 million to repurchase 759,056 ordinary shares on March 27. Year-to-date in 2026, the Company has deployed over RMB540 million toward share repurchases. This move underscores the Company's ongoing commitment to shareholder returns.


Risks

  • Continued large share repurchases could strain the company's cash reserves, impacting capital available for growth investments.
  • Market volatility may affect the effectiveness of the buyback program and the stock's valuation.
  • Dependence on the Chinese job recruitment market could pose risks if economic conditions deteriorate.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026